US Patent

US12296050 — Pharmaceutical compositions comprising maralixibat and uses thereof

Method of Use · Assigned to Mirum Pharmaceuticals Inc · Expires 2043-10-05 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition containing maralixibat or a salt thereof, used as a solid dosage drug product for treating cholestatic pruritus and liver disease.

USPTO Abstract

The invention relates to a pharmaceutical composition comprising maralixibat, or a pharmaceutically acceptable salt thereof, as the active ingredient. The invention further relates to the use of the pharmaceutical composition as a solid dosage drug product. The invention also relates to the use of the pharmaceutical composition and the solid dosage drug product described herein for treating cholestatic pruritus and cholestatic liver disease.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4187 maralixibat-chloride
U-4187 maralixibat-chloride
U-4186 maralixibat-chloride
U-4187 maralixibat-chloride

Patent Metadata

Patent number
US12296050
Jurisdiction
US
Classification
Method of Use
Expires
2043-10-05
Drug substance claim
No
Drug product claim
Yes
Assignee
Mirum Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.